{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "ORPHAN DRUG|Designated/Approved|Treatment of diffuse large B-cell lymphoma" in comments (approximate match)
Showing 1 - 9 of 9 results
Status:
US Approved Rx
(2004)
Source:
BLA021665
(2004)
Source URL:
First approved in 1949
Class:
MIXTURE
Status:
US Approved Rx
(2021)
Source:
BLA761196
(2021)
Source URL:
First approved in 2021
Source:
BLA761196
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2020)
Source:
BLA761163
(2020)
Source URL:
First approved in 2020
Source:
BLA761163
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2019)
Source:
BLA761121
(2019)
Source URL:
First approved in 2019
Source:
BLA761121
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2020)
Source:
BLA761140
(2020)
Source URL:
First approved in 1997
Source:
BLA103705
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2017)
First approved in 2017
Class:
STRUCTURALLY DIVERSE
Status:
US Approved Rx
(2017)
First approved in 2017
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
BLA125714
(2021)
Source URL:
First approved in 2021
Source:
BLA125714
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
US Approved Rx
(2019)
Source:
NDA212306
(2019)
Source URL:
First approved in 2019
Source:
NDA212306
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Selinexor (KPT-330) is a first in class XPO1 antagonist being evaluated in multiple later stage clinical trials in patients with relapsed and/or refractory hematological and solid tumor malignancies.
